Review



human plk1 cdna carcer  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Addgene inc human plk1 cdna carcer
    Figure 1. <t>Plk1</t> overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).
    Human Plk1 Cdna Carcer, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 68 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plk1 cdna carcer/product/Addgene inc
    Average 94 stars, based on 68 article reviews
    human plk1 cdna carcer - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer."

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer.

    Journal: Cell reports

    doi: 10.1016/j.celrep.2023.113266

    Figure 1. Plk1 overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).
    Figure Legend Snippet: Figure 1. Plk1 overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).

    Techniques Used: Over Expression, RNA Sequencing



    Similar Products

    92
    Sino Biological plk1
    Plk1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plk1/product/Sino Biological
    Average 92 stars, based on 1 article reviews
    plk1 - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    94
    Addgene inc human plk1 cdna carcer
    Figure 1. <t>Plk1</t> overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).
    Human Plk1 Cdna Carcer, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plk1 cdna carcer/product/Addgene inc
    Average 94 stars, based on 1 article reviews
    human plk1 cdna carcer - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    91
    Cusabio cdna sequence encoding plk1
    ( A ) Volcano plots showing HILPS interacting proteins pulled down from 293T cells exposed to 1% O 2 using biotin-labeled HILPS . Proteins significantly enriched (fold change > 2 and P < 0.01) from three independent experiments are displayed as red dots. ( B ) Biotin-labeled HILPS pull-down assay using 293T cell lysates with respective hemagglutinin (HA)–tagged protein expression. IB, immunoblot. ( C ) Biotin-labeled HILPS pull-down assay to detect endogenous <t>PLK1</t> in 1% O 2 -treated cells. ( D ) In vitro RNA pull-down assay using biotin-labeled HILPS and recombinant GST-PLK1. ( E ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells exposed to 1% O 2 . ( F ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells treated with MG132 (10 μM) for 6 hours before harvest. ( G ) Time-course analysis of PLK1 degradation. HILPS -depleted NCM460 and RKO cells were cultured in 1% O 2 , treated with cycloheximide (CHX; 100 μg/ml) and harvested at the indicated time points, followed by immunoblotting of PLK1. ( H ) Analysis of PLK1 polyubiquitination in the presence or absence of HILPS in 293T cells. ( I ) Immunoblots of PLK1 and CDH1 in 1% O 2 -cultured NCM460 and RKO cells expressing shRNA targeting HILPS and/or CDH1 . Asterisk denotes a nonspecific band detected by CDH1 antibody. ( J ) Immunoblots of indicated proteins in 293T cells transfected with HA-PLK1, Flag-CDH1, and/or HILPS . ( K ) Co-IP to detect protein interaction between PLK1 and CDH1 in the absence or presence of HILPS . 293T cells were treated with MG132 (10 μM) for 6 hours before harvest. ( L ) In vitro protein binding assay to detect PLK1-CDH1 interaction in the absence or presence of in vitro transcribed HILPS .
    Cdna Sequence Encoding Plk1, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdna sequence encoding plk1/product/Cusabio
    Average 91 stars, based on 1 article reviews
    cdna sequence encoding plk1 - by Bioz Stars, 2026-06
    91/100 stars
      Buy from Supplier

    93
    Addgene inc human plk1 cdna
    A) Schematic representation showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and <t>Her2-Plk1</t> overexpression results in high CIN tumors. B ) Average SCNAs in Her2 and Her2/Plk1 tumors; Unpaired t test, p = 0.012. C ) SCNAs in 10 Her2 and 10 Her2/Plk1 mammary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss (PCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-sequencing. Heatmap showing differentially expressed cell cycle and SASP-related genes (Fold change (FC) > 1.5 or < −1.5, p <0.05, n=3 tumors per genotype). E) GSEA using gene sets from KEGG pathways as analyzed by cluster profiler. Pathways overrepresented in Her2-Plk1 tumors are shown in yellow, whereas pathways overrepresented in Her2 tumors are displayed in blue. F) Fluorometric measurement of ß-galactosidase activity in Her2 and Her2-Plk1 tumor lysates (Mann Whitney test p<0.005**, n=10 (Her2) and n=16 (Her2-Plk1)). G) Cytokine array of tumor lysates of Her2 and Her2-Plk1 showing increased CXCL1, IL16 and IL1RN in the high CIN group (p<0.05* p<0.0005***, 2-way ANOVA, Sidak’s multiple comparison test, n=3). H) Characterization of TAM’s and monocytes. Live CD45 + CD11b + cells were divided into two groups based on Ly6C and MHCII. Flow cytometric analysis of inflammatory monocytes (Ly6c high MHCII low ) and M1 TAMs (Ly6c low MHCII high) in endpoint tumors (p<0.05*, n=5 (Her2) and n=8 (Her2-Plk1)).
    Human Plk1 Cdna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human plk1 cdna/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    human plk1 cdna - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    OriGene length plk1 cdna
    A) Schematic representation showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and <t>Her2-Plk1</t> overexpression results in high CIN tumors. B ) Average SCNAs in Her2 and Her2/Plk1 tumors; Unpaired t test, p = 0.012. C ) SCNAs in 10 Her2 and 10 Her2/Plk1 mammary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss (PCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-sequencing. Heatmap showing differentially expressed cell cycle and SASP-related genes (Fold change (FC) > 1.5 or < −1.5, p <0.05, n=3 tumors per genotype). E) GSEA using gene sets from KEGG pathways as analyzed by cluster profiler. Pathways overrepresented in Her2-Plk1 tumors are shown in yellow, whereas pathways overrepresented in Her2 tumors are displayed in blue. F) Fluorometric measurement of ß-galactosidase activity in Her2 and Her2-Plk1 tumor lysates (Mann Whitney test p<0.005**, n=10 (Her2) and n=16 (Her2-Plk1)). G) Cytokine array of tumor lysates of Her2 and Her2-Plk1 showing increased CXCL1, IL16 and IL1RN in the high CIN group (p<0.05* p<0.0005***, 2-way ANOVA, Sidak’s multiple comparison test, n=3). H) Characterization of TAM’s and monocytes. Live CD45 + CD11b + cells were divided into two groups based on Ly6C and MHCII. Flow cytometric analysis of inflammatory monocytes (Ly6c high MHCII low ) and M1 TAMs (Ly6c low MHCII high) in endpoint tumors (p<0.05*, n=5 (Her2) and n=8 (Her2-Plk1)).
    Length Plk1 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/length plk1 cdna/product/OriGene
    Average 93 stars, based on 1 article reviews
    length plk1 cdna - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    OriGene plasmid encoding the full-length plk1 cdna
    A) Schematic representation showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and <t>Her2-Plk1</t> overexpression results in high CIN tumors. B ) Average SCNAs in Her2 and Her2/Plk1 tumors; Unpaired t test, p = 0.012. C ) SCNAs in 10 Her2 and 10 Her2/Plk1 mammary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss (PCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-sequencing. Heatmap showing differentially expressed cell cycle and SASP-related genes (Fold change (FC) > 1.5 or < −1.5, p <0.05, n=3 tumors per genotype). E) GSEA using gene sets from KEGG pathways as analyzed by cluster profiler. Pathways overrepresented in Her2-Plk1 tumors are shown in yellow, whereas pathways overrepresented in Her2 tumors are displayed in blue. F) Fluorometric measurement of ß-galactosidase activity in Her2 and Her2-Plk1 tumor lysates (Mann Whitney test p<0.005**, n=10 (Her2) and n=16 (Her2-Plk1)). G) Cytokine array of tumor lysates of Her2 and Her2-Plk1 showing increased CXCL1, IL16 and IL1RN in the high CIN group (p<0.05* p<0.0005***, 2-way ANOVA, Sidak’s multiple comparison test, n=3). H) Characterization of TAM’s and monocytes. Live CD45 + CD11b + cells were divided into two groups based on Ly6C and MHCII. Flow cytometric analysis of inflammatory monocytes (Ly6c high MHCII low ) and M1 TAMs (Ly6c low MHCII high) in endpoint tumors (p<0.05*, n=5 (Her2) and n=8 (Her2-Plk1)).
    Plasmid Encoding The Full Length Plk1 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmid encoding the full-length plk1 cdna/product/OriGene
    Average 90 stars, based on 1 article reviews
    plasmid encoding the full-length plk1 cdna - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Genechem cdna sequences of shc1, shcbp1, plk1, and misp gene
    a <t>Shc1-binding</t> proteins in SNU-216 cells identified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis. b Gene expression correlation of Shc1-binding proteins and HER2 in 659 gastric cancer tissues from GEO data (GSE62254, GSE15459, GSE34942, and GSE54129). Representative scatter plot of SHCBP1 and HER2 is shown. The p values were determined by two-sided Spearman’s rank correlation test ( n = 659 independent biological samples). c Gene expression profiles of the cancer and corresponding adjacent normal tissues from 16 patients detected using mRNA microarrays. The upregulated Shc1-binding proteins are marked in red and the representative raw count of SHCBP1 is shown. d A Venn diagram showing the overlap of Shc1-binding proteins, cancer upregulated proteins, and proteins correlated with HER2 expression. e mRNA expression of identified Shc1-binding proteins ( SHCBP1 , JUP , LYN , EPHA2 , and RASAL2 ) in seven patients with HER2-positive gastric cancer detected by real-time PCR. Data are the mean ± standard error of the mean (s.e.m). The p values were determined by paired two-sided Student’s t test or nonparametric test ( n = 7 independent biological samples). f Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 in SNU-216 cells treated with 100 ng/mL epidermal growth factor (EGF) for the indicated times. IP immunoprecipitation, WCL whole cell lysates. g Fluorescence resonance energy transfer (FRET) assay of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with 100 ng/mL EGF for the indicated times. Data are the mean ± s.e.m. The p values were determined by repeated measures one-way ANOVA ( n = 105 independent cells per group). h Immunofluorescence colocalization of Shc1 and HER2 in SNU-216 cells treated with/without 100 ng/mL EGF. Cells were immunostained with anti-ERBB2 antibody (red), anti-Shc1 antibody (green), and DAPI (blue). i Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 treated with EGF and/or trastuzumab (Trast). j FRET assays of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with EGF and/or trastuzumab. Data are the mean ± s.e.m. The p values were determined by two-sided nonparametric test ( n = 130 independent cells per group). Data of f and i are representative of at least two independent experiments. Data of h are representative of at least three independent experiments.
    Cdna Sequences Of Shc1, Shcbp1, Plk1, And Misp Gene, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdna sequences of shc1, shcbp1, plk1, and misp gene/product/Genechem
    Average 90 stars, based on 1 article reviews
    cdna sequences of shc1, shcbp1, plk1, and misp gene - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. Plk1 overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).

    Journal: Cell reports

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer.

    doi: 10.1016/j.celrep.2023.113266

    Figure Lengend Snippet: Figure 1. Plk1 overexpression drives inflammatory monocyte recruitment as a consequence of the SASP (A) Schematic showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. (B) Average SCNAs in 10 Her2 and 10 Her2-Plk1 tumors; unpaired t test, p = 0.0004. (C) SCNAs in 10 Her2 and 10 Her2-Plk1 mammary tumors. Shown are whole-chromosome gain (WCG) and whole-chromosome loss (WCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). (D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-seq. Heatmap showing differentially expressed cell cycle and SASP- related genes (fold change [FC] > 1.5 or < 1.5, p < 0.05, n = 3 tumors per genotype).

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Gene expression data Breast cancer METABRIC cohort, Pereira et al.50 https://cbioportal-datahub.s3. amazonaws.com/brca_metabric.tar.gz Experimental models: Cell lines MCF-7 Obtained from Guillermo de Cárcer Laboratory N/A Cal51 Obtained from Uri-Ben David Laboratory N/A Experimental models: Organisms/strains Mouse: TetO-Her2/Plk1/MMTV-rtTA, FVB Carcer et al.7 https://doi.org/10.1038/s41467-018-05429-5 Oligonucleotides Mycoplasma antisense primer MGSO (50-TGCACCATCTGTCACTCTGTTA ACCTC-30), (10 mM) Integrated DNA Technologies https://doi.org/10.1038/nprot.2010.43 Mycoplasma sense primer GPO-3 (50-GGGAGCAAACAGGATTAGATA CCCT-30), (10 mM) Integrated DNA Technologies https://doi.org/10.1038/nprot.2010.43 Recombinant DNA pLenti CMVtight Hygro DEST Addgene #26433 Human PLK1 cDNA Carcer et al.7 https://doi.org/10.1038/s41467-018-05429-5 Software and algorithms GraphPad Prism 8 and 9 GraphPad Software https://www.graphpad.com/ scientific-software/prism/ FlowJo ImageJ software FlowJo https://imagej.net/plugins/flowj StrataQuest software TissueGnostics https://tissuegnostics.com/products/ contextual-image-analysis/strataquest R, Version 4.3.0 R Project for Statistical Computing https://www.r-project.org/ Seurat Hao et al.58; https://satijalab.org/seurat/ https://cloud.r-project.org/web/ packages/Seurat/index.html SingleR Aran et al.29 https://bioconductor.org/packages/ release/bioc/html/SingleR.html clusterProfiler Yu et al.59 https://bioconductor.org/packages/ release/bioc/html/clusterProfiler.html Python Python Software Foundation https://www.python.org/ matplotlib Hunter et al.60 https://matplotlib.org/

    Techniques: Over Expression, RNA Sequencing

    ( A ) Volcano plots showing HILPS interacting proteins pulled down from 293T cells exposed to 1% O 2 using biotin-labeled HILPS . Proteins significantly enriched (fold change > 2 and P < 0.01) from three independent experiments are displayed as red dots. ( B ) Biotin-labeled HILPS pull-down assay using 293T cell lysates with respective hemagglutinin (HA)–tagged protein expression. IB, immunoblot. ( C ) Biotin-labeled HILPS pull-down assay to detect endogenous PLK1 in 1% O 2 -treated cells. ( D ) In vitro RNA pull-down assay using biotin-labeled HILPS and recombinant GST-PLK1. ( E ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells exposed to 1% O 2 . ( F ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells treated with MG132 (10 μM) for 6 hours before harvest. ( G ) Time-course analysis of PLK1 degradation. HILPS -depleted NCM460 and RKO cells were cultured in 1% O 2 , treated with cycloheximide (CHX; 100 μg/ml) and harvested at the indicated time points, followed by immunoblotting of PLK1. ( H ) Analysis of PLK1 polyubiquitination in the presence or absence of HILPS in 293T cells. ( I ) Immunoblots of PLK1 and CDH1 in 1% O 2 -cultured NCM460 and RKO cells expressing shRNA targeting HILPS and/or CDH1 . Asterisk denotes a nonspecific band detected by CDH1 antibody. ( J ) Immunoblots of indicated proteins in 293T cells transfected with HA-PLK1, Flag-CDH1, and/or HILPS . ( K ) Co-IP to detect protein interaction between PLK1 and CDH1 in the absence or presence of HILPS . 293T cells were treated with MG132 (10 μM) for 6 hours before harvest. ( L ) In vitro protein binding assay to detect PLK1-CDH1 interaction in the absence or presence of in vitro transcribed HILPS .

    Journal: Science Advances

    Article Title: HILPS , a long noncoding RNA essential for global oxygen sensing in humans

    doi: 10.1126/sciadv.adi1867

    Figure Lengend Snippet: ( A ) Volcano plots showing HILPS interacting proteins pulled down from 293T cells exposed to 1% O 2 using biotin-labeled HILPS . Proteins significantly enriched (fold change > 2 and P < 0.01) from three independent experiments are displayed as red dots. ( B ) Biotin-labeled HILPS pull-down assay using 293T cell lysates with respective hemagglutinin (HA)–tagged protein expression. IB, immunoblot. ( C ) Biotin-labeled HILPS pull-down assay to detect endogenous PLK1 in 1% O 2 -treated cells. ( D ) In vitro RNA pull-down assay using biotin-labeled HILPS and recombinant GST-PLK1. ( E ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells exposed to 1% O 2 . ( F ) Immunoblots of PLK1 in HILPS -depleted NCM460 and RKO cells treated with MG132 (10 μM) for 6 hours before harvest. ( G ) Time-course analysis of PLK1 degradation. HILPS -depleted NCM460 and RKO cells were cultured in 1% O 2 , treated with cycloheximide (CHX; 100 μg/ml) and harvested at the indicated time points, followed by immunoblotting of PLK1. ( H ) Analysis of PLK1 polyubiquitination in the presence or absence of HILPS in 293T cells. ( I ) Immunoblots of PLK1 and CDH1 in 1% O 2 -cultured NCM460 and RKO cells expressing shRNA targeting HILPS and/or CDH1 . Asterisk denotes a nonspecific band detected by CDH1 antibody. ( J ) Immunoblots of indicated proteins in 293T cells transfected with HA-PLK1, Flag-CDH1, and/or HILPS . ( K ) Co-IP to detect protein interaction between PLK1 and CDH1 in the absence or presence of HILPS . 293T cells were treated with MG132 (10 μM) for 6 hours before harvest. ( L ) In vitro protein binding assay to detect PLK1-CDH1 interaction in the absence or presence of in vitro transcribed HILPS .

    Article Snippet: His-CDH1 protein was purchased from CUSABIO. cDNA sequence encoding PLK1 was cloned into the pGEX-4T vector, in frame with GST.

    Techniques: Labeling, Pull Down Assay, Expressing, Western Blot, In Vitro, Recombinant, Cell Culture, shRNA, Transfection, Co-Immunoprecipitation Assay, Protein Binding

    ( A to C ) Venn diagram of differentially expressed genes (DEGs) resulting from 1% O 2 -cultured H9 cells expressing sh HILPS #1 or sh HILPS #2 (A). Heatmap presentation (B) and enrichment analysis (C) of 4453 merged DEG in (A). Pathway enrichment was analyzed by Metascape ( www.metascape.org ). TNFα, tumor necrosis factor–α; NFκB, nuclear factor κB. ( D ) Gene set enrichment analysis of HIF1α target gene sets in the expression profiles of H9 cells expressing HILPS shRNA#1 ( software.broadinstitute.org/gsea ). NES, normalized enrichment score; FDR, false discovery rate. ( E ) qPCR analysis of HIF1α target genes in HILPS -depleted H9 cells exposed to 1% O 2 . ( F ) qPCR analysis of HIF1 α mRNA in HILPS -depleted cells exposed to 1% O 2 . ( G ) Immunoblots of HIF1α in HILPS -depleted cells treated with MG132 (10 μM) for 6 hours before harvest. ( H ) Biotin-labeled HILPS pull-down assay using lysates from 293T cells expressing tagged proteins. ( I ) Immunoblots of HIF1α and PLK1 in HILPS -depleted cells with or without Flag-PLK1 overexpression. ( J ) Immunoblots of HIF1α and PLK1 in PLK1 -depleted (top) or BI6727-treated (bottom) RKO cells subjected to 1% O 2 exposure. ( K and L ) Time-course analysis of HIF1α degradation in PLK1 -depleted (top) or BI6727-treated (bottom) RKO cells subjected to 1% O 2 exposure. HIF1α was analyzed by immunoblotting (K) and quantified as shown in (L). ( M ) Cell death analysis of HILPS -depleted cells cultured in 1% O 2 with or without ectopic HIF1α. ( N and O ) Tumor growth of HILPS -depleted HCT116 xenografts with or without ectopic HIF1α ( n = 5) (N). Tumors were dissected 2 weeks after engraftment (O). Data shown are means ± SD from biological triplicates. ** P < 0.01 and *** P < 0.001; unpaired two-tailed Student’s t test [(E) and (F)] and one-way ANOVA [(M) and (N)].

    Journal: Science Advances

    Article Title: HILPS , a long noncoding RNA essential for global oxygen sensing in humans

    doi: 10.1126/sciadv.adi1867

    Figure Lengend Snippet: ( A to C ) Venn diagram of differentially expressed genes (DEGs) resulting from 1% O 2 -cultured H9 cells expressing sh HILPS #1 or sh HILPS #2 (A). Heatmap presentation (B) and enrichment analysis (C) of 4453 merged DEG in (A). Pathway enrichment was analyzed by Metascape ( www.metascape.org ). TNFα, tumor necrosis factor–α; NFκB, nuclear factor κB. ( D ) Gene set enrichment analysis of HIF1α target gene sets in the expression profiles of H9 cells expressing HILPS shRNA#1 ( software.broadinstitute.org/gsea ). NES, normalized enrichment score; FDR, false discovery rate. ( E ) qPCR analysis of HIF1α target genes in HILPS -depleted H9 cells exposed to 1% O 2 . ( F ) qPCR analysis of HIF1 α mRNA in HILPS -depleted cells exposed to 1% O 2 . ( G ) Immunoblots of HIF1α in HILPS -depleted cells treated with MG132 (10 μM) for 6 hours before harvest. ( H ) Biotin-labeled HILPS pull-down assay using lysates from 293T cells expressing tagged proteins. ( I ) Immunoblots of HIF1α and PLK1 in HILPS -depleted cells with or without Flag-PLK1 overexpression. ( J ) Immunoblots of HIF1α and PLK1 in PLK1 -depleted (top) or BI6727-treated (bottom) RKO cells subjected to 1% O 2 exposure. ( K and L ) Time-course analysis of HIF1α degradation in PLK1 -depleted (top) or BI6727-treated (bottom) RKO cells subjected to 1% O 2 exposure. HIF1α was analyzed by immunoblotting (K) and quantified as shown in (L). ( M ) Cell death analysis of HILPS -depleted cells cultured in 1% O 2 with or without ectopic HIF1α. ( N and O ) Tumor growth of HILPS -depleted HCT116 xenografts with or without ectopic HIF1α ( n = 5) (N). Tumors were dissected 2 weeks after engraftment (O). Data shown are means ± SD from biological triplicates. ** P < 0.01 and *** P < 0.001; unpaired two-tailed Student’s t test [(E) and (F)] and one-way ANOVA [(M) and (N)].

    Article Snippet: His-CDH1 protein was purchased from CUSABIO. cDNA sequence encoding PLK1 was cloned into the pGEX-4T vector, in frame with GST.

    Techniques: Cell Culture, Expressing, shRNA, Software, Western Blot, Labeling, Pull Down Assay, Over Expression, Two Tailed Test

    ( A ) Co-IP of endogenous HIF1α and PLK1 using lysates of 1% O 2 -cultured NCM460 and RKO cells. ( B ) Immunoblots of indicated proteins in 293T cells expressing Flag-HIF1α, HA-VHL, and/or PLK1 (T210D and K82R). ( C ) Time-course analysis of Flag-HIF1α in 293T cells coexpressing PLK1 T210D or K82R. Flag-HIF1α protein levels were analyzed by immunoblotting. ( D ) In vitro kinase assay of recombinant GST-HIF1α catalyzed by Flag-tagged PLK1 T210D or K82R purified from 293T cells. Phosphorylated proteins were separated by SDS–polyacrylamide gel electrophoresis (PAGE) and visualized by autoradiography. Loading controls were shown as Coomassie blue staining in the bottom panels. ( E ) In vitro kinase analysis of recombinant GST-HIF1α. Active human WT PLK1 proteins were incubated with GST-HIF1α (WT, T218A, or S463A) for kinase reaction. HIF1α phosphorylation signals were detected as in (D). ( F ) Peptide sequence alignment of HIF1α (amino acid 215 to 221) in multiple species. The threonine-218 residue is highlighted in red. ( G and H ) Time-course analysis of Flag-HIF1α WT or mutants (T218D or T218A) degradation in 293T cells by immunoblot (G) with quantification shown in (H). ( I ) Analysis of Flag-HIF1α WT or mutants (T218D or T218A) polyubiquitylation. Myc-tagged ubiquitin was cotransfected with Flag-HIF1α (WT or mutants) into 293T cells, and the resulting cell lysates were subjected to co-IP, followed by polyubiquitylation detection. ( J ) Co-IP of Flag-HIF1α (WT or mutants) and HA-VHL using 293T cell lysate with epitope-tagged proteins expression. MG132 (10 μM) was added to prevent HIF1α degradation. Data shown are means ± SD from biological triplicates.

    Journal: Science Advances

    Article Title: HILPS , a long noncoding RNA essential for global oxygen sensing in humans

    doi: 10.1126/sciadv.adi1867

    Figure Lengend Snippet: ( A ) Co-IP of endogenous HIF1α and PLK1 using lysates of 1% O 2 -cultured NCM460 and RKO cells. ( B ) Immunoblots of indicated proteins in 293T cells expressing Flag-HIF1α, HA-VHL, and/or PLK1 (T210D and K82R). ( C ) Time-course analysis of Flag-HIF1α in 293T cells coexpressing PLK1 T210D or K82R. Flag-HIF1α protein levels were analyzed by immunoblotting. ( D ) In vitro kinase assay of recombinant GST-HIF1α catalyzed by Flag-tagged PLK1 T210D or K82R purified from 293T cells. Phosphorylated proteins were separated by SDS–polyacrylamide gel electrophoresis (PAGE) and visualized by autoradiography. Loading controls were shown as Coomassie blue staining in the bottom panels. ( E ) In vitro kinase analysis of recombinant GST-HIF1α. Active human WT PLK1 proteins were incubated with GST-HIF1α (WT, T218A, or S463A) for kinase reaction. HIF1α phosphorylation signals were detected as in (D). ( F ) Peptide sequence alignment of HIF1α (amino acid 215 to 221) in multiple species. The threonine-218 residue is highlighted in red. ( G and H ) Time-course analysis of Flag-HIF1α WT or mutants (T218D or T218A) degradation in 293T cells by immunoblot (G) with quantification shown in (H). ( I ) Analysis of Flag-HIF1α WT or mutants (T218D or T218A) polyubiquitylation. Myc-tagged ubiquitin was cotransfected with Flag-HIF1α (WT or mutants) into 293T cells, and the resulting cell lysates were subjected to co-IP, followed by polyubiquitylation detection. ( J ) Co-IP of Flag-HIF1α (WT or mutants) and HA-VHL using 293T cell lysate with epitope-tagged proteins expression. MG132 (10 μM) was added to prevent HIF1α degradation. Data shown are means ± SD from biological triplicates.

    Article Snippet: His-CDH1 protein was purchased from CUSABIO. cDNA sequence encoding PLK1 was cloned into the pGEX-4T vector, in frame with GST.

    Techniques: Co-Immunoprecipitation Assay, Cell Culture, Western Blot, Expressing, In Vitro, Kinase Assay, Recombinant, Purification, Polyacrylamide Gel Electrophoresis, Autoradiography, Staining, Incubation, Phospho-proteomics, Sequencing, Residue, Ubiquitin Proteomics

    ( A ) qPCR analysis of HILPS in human normal and tumor organoids exposed to 21 or 1% O 2 for 24 hours. ( B ) Immunoblots of PLK1 and HIF1α in 1% O 2 -treated human organoids derived from normal colon tissue and colorectal cancer upon HILPS depletion. ( C to E ) Heatmap presentation of all DEG upon HILPS depletion by shRNA#1 in colorectal cancer organoids exposed to 1% O 2 (C). Pathway enrichment analysis of DEG by Metascape (D). Gene set enrichment analysis of HIF1α target gene sets in the expression profiles of HILPS -depleted colorectal cancer organoids (E). ( F ) Proliferation of colorectal cancer organoids exposed to 1% O 2 upon HILPS depletion. Organoid proliferation was assessed by CCK-8. OD, optical density. ( G ) Representative bright field images of colorectal cancer organoids cultured under 1% O 2 upon HILPS depletion (left). Scale bars, 200 μm. Quantitation of viable organoid colonies is shown on the right. ( H ) Representative images showing bright-field view and immunofluorescence staining of Ki67 in HILPS -depleted colorectal cancer organoids cultured under 1% O 2 (left). DAPI was stained to visualize the organoids in dark field. Scale bar, 200 μm. Quantitation of Ki67 positive staining cells per budding are presented (right). ( I ) Schematic depicting patient-derived organoid–based xenograft model. ( J ) Representative images of colorectal cancer organoid–based tumors in the subrenal capsule with or without HILPS depletion (left) and measurement of tumor volumes ( n = 5) (right). Data shown are means ± SD from biological triplicates. ** P < 0.01 and *** P < 0.001; unpaired two-tailed Student’s t test [(A), (F), (G), and (H)] and one-way ANOVA (J).

    Journal: Science Advances

    Article Title: HILPS , a long noncoding RNA essential for global oxygen sensing in humans

    doi: 10.1126/sciadv.adi1867

    Figure Lengend Snippet: ( A ) qPCR analysis of HILPS in human normal and tumor organoids exposed to 21 or 1% O 2 for 24 hours. ( B ) Immunoblots of PLK1 and HIF1α in 1% O 2 -treated human organoids derived from normal colon tissue and colorectal cancer upon HILPS depletion. ( C to E ) Heatmap presentation of all DEG upon HILPS depletion by shRNA#1 in colorectal cancer organoids exposed to 1% O 2 (C). Pathway enrichment analysis of DEG by Metascape (D). Gene set enrichment analysis of HIF1α target gene sets in the expression profiles of HILPS -depleted colorectal cancer organoids (E). ( F ) Proliferation of colorectal cancer organoids exposed to 1% O 2 upon HILPS depletion. Organoid proliferation was assessed by CCK-8. OD, optical density. ( G ) Representative bright field images of colorectal cancer organoids cultured under 1% O 2 upon HILPS depletion (left). Scale bars, 200 μm. Quantitation of viable organoid colonies is shown on the right. ( H ) Representative images showing bright-field view and immunofluorescence staining of Ki67 in HILPS -depleted colorectal cancer organoids cultured under 1% O 2 (left). DAPI was stained to visualize the organoids in dark field. Scale bar, 200 μm. Quantitation of Ki67 positive staining cells per budding are presented (right). ( I ) Schematic depicting patient-derived organoid–based xenograft model. ( J ) Representative images of colorectal cancer organoid–based tumors in the subrenal capsule with or without HILPS depletion (left) and measurement of tumor volumes ( n = 5) (right). Data shown are means ± SD from biological triplicates. ** P < 0.01 and *** P < 0.001; unpaired two-tailed Student’s t test [(A), (F), (G), and (H)] and one-way ANOVA (J).

    Article Snippet: His-CDH1 protein was purchased from CUSABIO. cDNA sequence encoding PLK1 was cloned into the pGEX-4T vector, in frame with GST.

    Techniques: Western Blot, Derivative Assay, shRNA, Expressing, CCK-8 Assay, Cell Culture, Quantitation Assay, Immunofluorescence, Staining, Two Tailed Test

    A) Schematic representation showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. B ) Average SCNAs in Her2 and Her2/Plk1 tumors; Unpaired t test, p = 0.012. C ) SCNAs in 10 Her2 and 10 Her2/Plk1 mammary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss (PCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-sequencing. Heatmap showing differentially expressed cell cycle and SASP-related genes (Fold change (FC) > 1.5 or < −1.5, p <0.05, n=3 tumors per genotype). E) GSEA using gene sets from KEGG pathways as analyzed by cluster profiler. Pathways overrepresented in Her2-Plk1 tumors are shown in yellow, whereas pathways overrepresented in Her2 tumors are displayed in blue. F) Fluorometric measurement of ß-galactosidase activity in Her2 and Her2-Plk1 tumor lysates (Mann Whitney test p<0.005**, n=10 (Her2) and n=16 (Her2-Plk1)). G) Cytokine array of tumor lysates of Her2 and Her2-Plk1 showing increased CXCL1, IL16 and IL1RN in the high CIN group (p<0.05* p<0.0005***, 2-way ANOVA, Sidak’s multiple comparison test, n=3). H) Characterization of TAM’s and monocytes. Live CD45 + CD11b + cells were divided into two groups based on Ly6C and MHCII. Flow cytometric analysis of inflammatory monocytes (Ly6c high MHCII low ) and M1 TAMs (Ly6c low MHCII high) in endpoint tumors (p<0.05*, n=5 (Her2) and n=8 (Her2-Plk1)).

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A) Schematic representation showing the mouse models used in this study, where Her2 mammary tumors show low levels of CIN and Her2-Plk1 overexpression results in high CIN tumors. B ) Average SCNAs in Her2 and Her2/Plk1 tumors; Unpaired t test, p = 0.012. C ) SCNAs in 10 Her2 and 10 Her2/Plk1 mammary tumors. Shown are whole chromosome gain (WCG) and loss (WCL), partial chromosome gain (PCG) and loss (PCL), focal amplification (AMP), deletion (DEL) and gross chromosomal rearrangement (GCR). D) Total transcriptome of Her2 and Her2-Plk1 tumor tissues was analyzed by bulk RNA-sequencing. Heatmap showing differentially expressed cell cycle and SASP-related genes (Fold change (FC) > 1.5 or < −1.5, p <0.05, n=3 tumors per genotype). E) GSEA using gene sets from KEGG pathways as analyzed by cluster profiler. Pathways overrepresented in Her2-Plk1 tumors are shown in yellow, whereas pathways overrepresented in Her2 tumors are displayed in blue. F) Fluorometric measurement of ß-galactosidase activity in Her2 and Her2-Plk1 tumor lysates (Mann Whitney test p<0.005**, n=10 (Her2) and n=16 (Her2-Plk1)). G) Cytokine array of tumor lysates of Her2 and Her2-Plk1 showing increased CXCL1, IL16 and IL1RN in the high CIN group (p<0.05* p<0.0005***, 2-way ANOVA, Sidak’s multiple comparison test, n=3). H) Characterization of TAM’s and monocytes. Live CD45 + CD11b + cells were divided into two groups based on Ly6C and MHCII. Flow cytometric analysis of inflammatory monocytes (Ly6c high MHCII low ) and M1 TAMs (Ly6c low MHCII high) in endpoint tumors (p<0.05*, n=5 (Her2) and n=8 (Her2-Plk1)).

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Over Expression, Amplification, RNA Sequencing, Activity Assay, MANN-WHITNEY, Comparison

    A) Expression of P38a and NF-kB-p65 in breast tumors from Her2 and Her2-Plk1 mice. Tumor cell lysates were used for immunodetection by using anti-PLK1, anti-NFkB-p65, anti-RELB, anti-P38, anti-pP38 and anti-vinculin as a loading control. Bar graphs represent the relative intensity of the signal from immunodetection (*, p<0.05, **, p<0.005, Mann-Whitney test, n=11 (Her2), n=14 (Her2-Plk1); numbers represent different tumors). B) Immunohistochemistry of PLK1, PD-L1 and CD206 in Her2 and Her2-Plk1 tumor sections and their corresponding bar graphs representing total sum area (μm 2 ). Positive regions per sample was calculated by dividing DAB positive area in each ROI/total area of the ROI (region of interest) and total sum area (μm 2 ) and adding positive regions in all the individual samples. Scale bar: 100μm. (*, p<0.05, **** p< 0.0001, Mann-Whitney test, n=5 (Her2), n=8 (Her2-Plk1)). C) Quantification of tumor-infiltrating lymphocytes in Her2 and Her2-Plk1 tumors and spleens. Representative two-parameter dot plots of CD45 + gated Tregs (CD25 + CD4 + Foxp3 + ), dendritic cells (CD11c + MHCII high ), NK cells (CD11c − Nkp46/Nk1.1 + )) and T cells (CD3 + CD4 + , CD3 + CD8 + ) in both spleen (n=5 (Her2), n=7 (Her2-Plk1)) and tumors (*, p<0.05, ** p<0.005, ***, p< 0.0005, Mann-Whitney test n=6 (Her2), n=10 (Her2-Plk1)) and bar graphs represented as % of CD45 positive cells. The numbers depicted in the boxes refer to the percentage of each cell type in different samples (Her2 and Her2-Plk1).

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A) Expression of P38a and NF-kB-p65 in breast tumors from Her2 and Her2-Plk1 mice. Tumor cell lysates were used for immunodetection by using anti-PLK1, anti-NFkB-p65, anti-RELB, anti-P38, anti-pP38 and anti-vinculin as a loading control. Bar graphs represent the relative intensity of the signal from immunodetection (*, p<0.05, **, p<0.005, Mann-Whitney test, n=11 (Her2), n=14 (Her2-Plk1); numbers represent different tumors). B) Immunohistochemistry of PLK1, PD-L1 and CD206 in Her2 and Her2-Plk1 tumor sections and their corresponding bar graphs representing total sum area (μm 2 ). Positive regions per sample was calculated by dividing DAB positive area in each ROI/total area of the ROI (region of interest) and total sum area (μm 2 ) and adding positive regions in all the individual samples. Scale bar: 100μm. (*, p<0.05, **** p< 0.0001, Mann-Whitney test, n=5 (Her2), n=8 (Her2-Plk1)). C) Quantification of tumor-infiltrating lymphocytes in Her2 and Her2-Plk1 tumors and spleens. Representative two-parameter dot plots of CD45 + gated Tregs (CD25 + CD4 + Foxp3 + ), dendritic cells (CD11c + MHCII high ), NK cells (CD11c − Nkp46/Nk1.1 + )) and T cells (CD3 + CD4 + , CD3 + CD8 + ) in both spleen (n=5 (Her2), n=7 (Her2-Plk1)) and tumors (*, p<0.05, ** p<0.005, ***, p< 0.0005, Mann-Whitney test n=6 (Her2), n=10 (Her2-Plk1)) and bar graphs represented as % of CD45 positive cells. The numbers depicted in the boxes refer to the percentage of each cell type in different samples (Her2 and Her2-Plk1).

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Expressing, Immunodetection, Control, MANN-WHITNEY, Immunohistochemistry

    A) Schematic depiction of isolation of hyperplastic mammary glands and FACS sorting of individual cells to obtain CD45 hematopoietic cells at early stage Her2 (16 days on doxycycline) and Her2-Plk1 (22 days on doxycycline) samples. Samples were extracted from three different mice per genotype from two mammary glands each. B) Clustered immune cell populations displayed by UMAP in all samples. The cell types in the clusters were annotated by using SingleR and gene expression information from the ImmGen reference database and displayed in a color-coded fashion. C) Volcano graph showing differentially expressed genes in the CD11b + CD11c − macrophage subtype with log2-fold change in gene expression versus -log10 of adjusted p-values. Genes that were found to be downregulated in Her2-Plk1 with respect to Her2 are shown in blue, while genes that were upregulated are shown in yellow (by a fold change of at least ±0.6 and an adjusted p-value of ≤0.05). D) Violin graphs showing the normalized expression levels of CD11b + CD24 − macrophages for genes related to antigen presentation, EMT and anti-inflammatory wound-healing phenotypes. Her2 samples are in blue and Her2-Plk1 in yellow. p-values adjusted for multiple testing are shown above each graph. Each dot represents the gene expression level of an individual cell.

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A) Schematic depiction of isolation of hyperplastic mammary glands and FACS sorting of individual cells to obtain CD45 hematopoietic cells at early stage Her2 (16 days on doxycycline) and Her2-Plk1 (22 days on doxycycline) samples. Samples were extracted from three different mice per genotype from two mammary glands each. B) Clustered immune cell populations displayed by UMAP in all samples. The cell types in the clusters were annotated by using SingleR and gene expression information from the ImmGen reference database and displayed in a color-coded fashion. C) Volcano graph showing differentially expressed genes in the CD11b + CD11c − macrophage subtype with log2-fold change in gene expression versus -log10 of adjusted p-values. Genes that were found to be downregulated in Her2-Plk1 with respect to Her2 are shown in blue, while genes that were upregulated are shown in yellow (by a fold change of at least ±0.6 and an adjusted p-value of ≤0.05). D) Violin graphs showing the normalized expression levels of CD11b + CD24 − macrophages for genes related to antigen presentation, EMT and anti-inflammatory wound-healing phenotypes. Her2 samples are in blue and Her2-Plk1 in yellow. p-values adjusted for multiple testing are shown above each graph. Each dot represents the gene expression level of an individual cell.

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Isolation, Gene Expression, Expressing, Immunopeptidomics

    A ) Survival analysis of Her2 (left) and Her2-Plk1 (right) tumors of mice treated with NK1.1 blocking antibody. Survival probability over time (upper graphs) and number and percentage of mice alive over time (lower table). The curves in light blue and light yellow depict untreated mice, whereas the curves in dark blue and dark yellow show mice treated with NK block, respectively. B) Normalized gene expression of CD27 versus Itgam ( CD11b ) in NK cells at the single cell level (individual dots) (Her2: blue, Her2-Plk1: yellow). The Spearman rank correlation coefficient across samples as well as the fold change and p-values adjusted for multiple testing for differential expression between Her2 and Her2-Plk1 samples are provided. C) Violin graphs showing the log-normalized gene expression values of NK cells in Her2 (blue) and Her2-Plk1 (yellow) tumors exemplarily shown for genes involved in cytotoxic response and surface receptors of NK cells. D) Heatmap showing normalized gene expression levels of differentially expressed effector genes, chemokines and their receptors, and activating receptor genes in NK cells. Each line represents a single cell. E) Gene set enrichment analysis for identification of pathways with enrichment of differentially expressed genes for two macrophage subsets and NK cells. Y-axis: hallmark signatures and X-axis: normalized enrichment scores with adjusted p-values, color-coded by the direction of the effect (yellow: upregulation in Her2-Plk1, blue: upregulation in Her2).

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A ) Survival analysis of Her2 (left) and Her2-Plk1 (right) tumors of mice treated with NK1.1 blocking antibody. Survival probability over time (upper graphs) and number and percentage of mice alive over time (lower table). The curves in light blue and light yellow depict untreated mice, whereas the curves in dark blue and dark yellow show mice treated with NK block, respectively. B) Normalized gene expression of CD27 versus Itgam ( CD11b ) in NK cells at the single cell level (individual dots) (Her2: blue, Her2-Plk1: yellow). The Spearman rank correlation coefficient across samples as well as the fold change and p-values adjusted for multiple testing for differential expression between Her2 and Her2-Plk1 samples are provided. C) Violin graphs showing the log-normalized gene expression values of NK cells in Her2 (blue) and Her2-Plk1 (yellow) tumors exemplarily shown for genes involved in cytotoxic response and surface receptors of NK cells. D) Heatmap showing normalized gene expression levels of differentially expressed effector genes, chemokines and their receptors, and activating receptor genes in NK cells. Each line represents a single cell. E) Gene set enrichment analysis for identification of pathways with enrichment of differentially expressed genes for two macrophage subsets and NK cells. Y-axis: hallmark signatures and X-axis: normalized enrichment scores with adjusted p-values, color-coded by the direction of the effect (yellow: upregulation in Her2-Plk1, blue: upregulation in Her2).

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Blocking Assay, Gene Expression, Quantitative Proteomics

    A) Volcano graph with reduced axes to focus on selected differentially expressed genes (labeled) in the B cell subset of Her2 and Her2-Plk1 tumors displayed as log2 fold change versus - log10 of the adjusted p-value. Genes that were found to be downregulated in Her2-Plk1 with respect to Her2 are shown in blue, while genes that were overexpressed are shown in yellow (by a fold change of at least ±0.4 and an adjusted p-value of ≤0.05). B) UMAP graph of T cells clustered into different T cell subtypes. Seven clusters with different cell types were identified after cell type annotation. C ) Relative distribution of the number of cells in each of the T cell subtypes with Her2 in blue and Her2-Plk1 in yellow. D) Normalized gene expression of Sell ( Cd62L ) versus Ccr7 in regulatory T cells at the single cell level (individual dots) (Her2: blue, Her2-Plk1: yellow). The Spearman rank correlation coefficient across samples as well as the fold change and p-values adjusted for multiple testing for differential expression between Her2 and Her2-Plk1 samples are provided. E) Volcano graph with reduced axes to focus on selected differentially expressed genes in the cluster of regulatory T cells displayed as log2 fold change versus -log10 of the adjusted p-value. Genes downregulated in Her2-Plk1 compared to Her2 are shown in blue, genes upregulated in Her2-Plk1 are displayed in yellow (by a fold change of at least ±0.4 and an adjusted p-value of ≤0.05).

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A) Volcano graph with reduced axes to focus on selected differentially expressed genes (labeled) in the B cell subset of Her2 and Her2-Plk1 tumors displayed as log2 fold change versus - log10 of the adjusted p-value. Genes that were found to be downregulated in Her2-Plk1 with respect to Her2 are shown in blue, while genes that were overexpressed are shown in yellow (by a fold change of at least ±0.4 and an adjusted p-value of ≤0.05). B) UMAP graph of T cells clustered into different T cell subtypes. Seven clusters with different cell types were identified after cell type annotation. C ) Relative distribution of the number of cells in each of the T cell subtypes with Her2 in blue and Her2-Plk1 in yellow. D) Normalized gene expression of Sell ( Cd62L ) versus Ccr7 in regulatory T cells at the single cell level (individual dots) (Her2: blue, Her2-Plk1: yellow). The Spearman rank correlation coefficient across samples as well as the fold change and p-values adjusted for multiple testing for differential expression between Her2 and Her2-Plk1 samples are provided. E) Volcano graph with reduced axes to focus on selected differentially expressed genes in the cluster of regulatory T cells displayed as log2 fold change versus -log10 of the adjusted p-value. Genes downregulated in Her2-Plk1 compared to Her2 are shown in blue, genes upregulated in Her2-Plk1 are displayed in yellow (by a fold change of at least ±0.4 and an adjusted p-value of ≤0.05).

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Labeling, Gene Expression, Quantitative Proteomics

    A) Schematic description of sorting PLK1 high versus PLK1 low tumors from the TCGA-BRCA cohort. A total of 186 (PLK1 high) and 165 (PLK1 low) tumors with a Z-score of +1 and –1, respectively, were identified. B) Unsupervised clustering of PLK1 high versus PLK1 low tumors using principal component analysis. Samples color-coded based on the groups (PLK1 low: blue, PLK1 high: yellow). C) Cellular deconvolution of PLK1 high and PLK1 low tumors using relative CIBERSORT to characterize the heterogeneity in immune cell composition of tumors with different levels of CIN. D) Heatmap showing gene expression data (Log 2 norm_count+1) and clustered into three different signatures associated with senescence, T-cell exhaustion and immune suppression from both PLK1 high (yellow) and PLK1 low (blue) tumor cohorts.

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet: A) Schematic description of sorting PLK1 high versus PLK1 low tumors from the TCGA-BRCA cohort. A total of 186 (PLK1 high) and 165 (PLK1 low) tumors with a Z-score of +1 and –1, respectively, were identified. B) Unsupervised clustering of PLK1 high versus PLK1 low tumors using principal component analysis. Samples color-coded based on the groups (PLK1 low: blue, PLK1 high: yellow). C) Cellular deconvolution of PLK1 high and PLK1 low tumors using relative CIBERSORT to characterize the heterogeneity in immune cell composition of tumors with different levels of CIN. D) Heatmap showing gene expression data (Log 2 norm_count+1) and clustered into three different signatures associated with senescence, T-cell exhaustion and immune suppression from both PLK1 high (yellow) and PLK1 low (blue) tumor cohorts.

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques: Gene Expression

    Journal: bioRxiv

    Article Title: Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer

    doi: 10.1101/2022.06.16.496429

    Figure Lengend Snippet:

    Article Snippet: These cells were then infected with an inducible Tet-ON lentivirus carrying the human PLK1 cDNA (pLenti CMVtight Hygro DEST from Addgene #26433) and selected with hygromycin (350 μg/ml).

    Techniques:

    a Shc1-binding proteins in SNU-216 cells identified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis. b Gene expression correlation of Shc1-binding proteins and HER2 in 659 gastric cancer tissues from GEO data (GSE62254, GSE15459, GSE34942, and GSE54129). Representative scatter plot of SHCBP1 and HER2 is shown. The p values were determined by two-sided Spearman’s rank correlation test ( n = 659 independent biological samples). c Gene expression profiles of the cancer and corresponding adjacent normal tissues from 16 patients detected using mRNA microarrays. The upregulated Shc1-binding proteins are marked in red and the representative raw count of SHCBP1 is shown. d A Venn diagram showing the overlap of Shc1-binding proteins, cancer upregulated proteins, and proteins correlated with HER2 expression. e mRNA expression of identified Shc1-binding proteins ( SHCBP1 , JUP , LYN , EPHA2 , and RASAL2 ) in seven patients with HER2-positive gastric cancer detected by real-time PCR. Data are the mean ± standard error of the mean (s.e.m). The p values were determined by paired two-sided Student’s t test or nonparametric test ( n = 7 independent biological samples). f Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 in SNU-216 cells treated with 100 ng/mL epidermal growth factor (EGF) for the indicated times. IP immunoprecipitation, WCL whole cell lysates. g Fluorescence resonance energy transfer (FRET) assay of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with 100 ng/mL EGF for the indicated times. Data are the mean ± s.e.m. The p values were determined by repeated measures one-way ANOVA ( n = 105 independent cells per group). h Immunofluorescence colocalization of Shc1 and HER2 in SNU-216 cells treated with/without 100 ng/mL EGF. Cells were immunostained with anti-ERBB2 antibody (red), anti-Shc1 antibody (green), and DAPI (blue). i Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 treated with EGF and/or trastuzumab (Trast). j FRET assays of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with EGF and/or trastuzumab. Data are the mean ± s.e.m. The p values were determined by two-sided nonparametric test ( n = 130 independent cells per group). Data of f and i are representative of at least two independent experiments. Data of h are representative of at least three independent experiments.

    Journal: Nature Communications

    Article Title: Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer

    doi: 10.1038/s41467-021-23053-8

    Figure Lengend Snippet: a Shc1-binding proteins in SNU-216 cells identified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis. b Gene expression correlation of Shc1-binding proteins and HER2 in 659 gastric cancer tissues from GEO data (GSE62254, GSE15459, GSE34942, and GSE54129). Representative scatter plot of SHCBP1 and HER2 is shown. The p values were determined by two-sided Spearman’s rank correlation test ( n = 659 independent biological samples). c Gene expression profiles of the cancer and corresponding adjacent normal tissues from 16 patients detected using mRNA microarrays. The upregulated Shc1-binding proteins are marked in red and the representative raw count of SHCBP1 is shown. d A Venn diagram showing the overlap of Shc1-binding proteins, cancer upregulated proteins, and proteins correlated with HER2 expression. e mRNA expression of identified Shc1-binding proteins ( SHCBP1 , JUP , LYN , EPHA2 , and RASAL2 ) in seven patients with HER2-positive gastric cancer detected by real-time PCR. Data are the mean ± standard error of the mean (s.e.m). The p values were determined by paired two-sided Student’s t test or nonparametric test ( n = 7 independent biological samples). f Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 in SNU-216 cells treated with 100 ng/mL epidermal growth factor (EGF) for the indicated times. IP immunoprecipitation, WCL whole cell lysates. g Fluorescence resonance energy transfer (FRET) assay of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with 100 ng/mL EGF for the indicated times. Data are the mean ± s.e.m. The p values were determined by repeated measures one-way ANOVA ( n = 105 independent cells per group). h Immunofluorescence colocalization of Shc1 and HER2 in SNU-216 cells treated with/without 100 ng/mL EGF. Cells were immunostained with anti-ERBB2 antibody (red), anti-Shc1 antibody (green), and DAPI (blue). i Co-immunoprecipitation assays of Flag-Shc1 together with HA-SHCBP1 treated with EGF and/or trastuzumab (Trast). j FRET assays of eCFP-Shc1 and eYFP-SHCBP1 in cells treated with EGF and/or trastuzumab. Data are the mean ± s.e.m. The p values were determined by two-sided nonparametric test ( n = 130 independent cells per group). Data of f and i are representative of at least two independent experiments. Data of h are representative of at least three independent experiments.

    Article Snippet: The cDNA sequences of Shc1 , SHCBP1 , PLK1 , and MISP gene (Genechem, China) were delivered into pLentiCMV-1 × Flag-puro vector (gift from Hui Sun Lab) for conditional expression, into pRK5-vector (gift from Hui Sun Lab) for temporary expression.

    Techniques: Binding Assay, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Gene Expression, Expressing, Real-time Polymerase Chain Reaction, Immunoprecipitation, Fluorescence, Förster Resonance Energy Transfer, Immunofluorescence

    In growth factor free condition, HER2 is inactivated and SHCBP1 acts as a Shc1-binding protein interacting with Shc1. Following growth factor stimuli, HER2 is activated through dimerization with other HER members and recruits Shc1 to evoke MAPK or PI3K pathways. Released SHCBP1 responds to HER2 cascade by translocating into the nucleus following Ser273 phosphorylation (pS273), and then contributing to cell mitosis regulation through binding with PLK1 to promote the phosphorylation of the mitotic interactor MISP. Hyperactivation of HER2–SHCBP1–PLK1 axis impairs the sensitivity of HER2-targeted therapy trastuzumab. The Inhibitor theaflavine-3, 3′-digallate (TFBG) blocks SHCBP1–PLK1 complex and renders gastric cancer sensitive to trastuzumab. TFBG–trastuzumab combination is highly efficacious to suppress gastric cancer growth.

    Journal: Nature Communications

    Article Title: Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer

    doi: 10.1038/s41467-021-23053-8

    Figure Lengend Snippet: In growth factor free condition, HER2 is inactivated and SHCBP1 acts as a Shc1-binding protein interacting with Shc1. Following growth factor stimuli, HER2 is activated through dimerization with other HER members and recruits Shc1 to evoke MAPK or PI3K pathways. Released SHCBP1 responds to HER2 cascade by translocating into the nucleus following Ser273 phosphorylation (pS273), and then contributing to cell mitosis regulation through binding with PLK1 to promote the phosphorylation of the mitotic interactor MISP. Hyperactivation of HER2–SHCBP1–PLK1 axis impairs the sensitivity of HER2-targeted therapy trastuzumab. The Inhibitor theaflavine-3, 3′-digallate (TFBG) blocks SHCBP1–PLK1 complex and renders gastric cancer sensitive to trastuzumab. TFBG–trastuzumab combination is highly efficacious to suppress gastric cancer growth.

    Article Snippet: The cDNA sequences of Shc1 , SHCBP1 , PLK1 , and MISP gene (Genechem, China) were delivered into pLentiCMV-1 × Flag-puro vector (gift from Hui Sun Lab) for conditional expression, into pRK5-vector (gift from Hui Sun Lab) for temporary expression.

    Techniques: Binding Assay, Phospho-proteomics